TREVI THERAPEUTIC DL-,001

Clear Street raises its price target for Trevi Therapeutics to $40 after GSK halted development of Camlipixant for refractory chronic cough. The removal of the competing drug increases the market potential for Trevi’s Haduvio, and analysts raise the assumed annual price of the therapy to $100,000. A recently completed financing strengthens the balance sheet and secures liquidity through 2030. » More on finanzen.net

Trevi Therapeutics' stock hit a new all‑time high of $19.33 and is currently trading at $19.48; year‑to‑date the share price has risen 226.05% and market capitalization is about $2.69 billion. InvestingPro views the stock as overvalued relative to its fair‑value estimate, while one analyst highlights the high annual return. Trevi reported strong cash reserves of about $334 million after an April offering, intended to fund operations through 2030, and is preparing a regulatory two‑study program for Haduvio in IPF‑CC following an end‑of‑phase‑2 meeting with the FDA; initial data are expected in 2027. Stifel confirmed the rating. » More on de.investing.com

After an equity placement in April, Trevi Therapeutics reports a pro-forma cash balance of about $334 million ($172 million on hand plus $162 million from the placement), securing liquidity through 2030. The company is advancing Phase III trials for its lead candidate Haduvio and plans several key clinical studies in 2026, including trials for chronic cough in IPF and non‑IPF ILD. Despite the stronger balance sheet, the shares dipped slightly after hours; risks remain from competition by other P2X3 antagonists such as Camlipixant and the absence of product-generated revenue. » More on de.investing.com